PMID- 35277202
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220322
IS  - 1710-1484 (Print)
IS  - 1710-1492 (Electronic)
IS  - 1710-1484 (Linking)
VI  - 18
IP  - 1
DP  - 2022 Mar 11
TI  - Intravenous immunoglobulins improve live birth rate among women with underlying 
      immune conditions and recurrent pregnancy loss: a systematic review and 
      meta-analysis.
PG  - 23
LID - 10.1186/s13223-022-00660-8 [doi]
LID - 23
AB  - Intravenous immunoglobulin (IVIG) is increasingly used as a treatment for 
      recurrent pregnancy loss (RPL) despite lack of clear evidence on efficacy. Recent 
      data suggest IVIG might be more effective in a subgroup of women with an aberrant 
      immunological profile. Therefore, a systematic review and meta-analysis of 
      studies on the effectiveness of IVIG treatment on pregnancy outcome among women 
      with RPL and underlying immunological conditions (e.g., elevated NK cell 
      percentage, elevated Th1/Th2 ratio, diagnosis with autoimmune disorders) was 
      conducted. Eight non-randomized controlled trials, including 478 women 
      (intervention: 284; control: 194), met eligibility criteria. Meta-analysis showed 
      that treatment with IVIG was associated with a two-fold increase in live birth 
      rate (RR 1.98, 95% CI 1.44-2.73, P < 0.0001). The effect of IVIG was particularly 
      marked in the subgroup of studies including patients based on presence of 
      elevated (> 12%) NK-cell percentage (RR 2.32, 95% CI 1.77-3.02, P < 0.0001) and 
      when starting intervention prior to or during cycle of conception (RR 4.47, 95% 
      CI 1.53-13.05, P = 0.006). In conclusion, treatment with IVIG may improve live 
      birth rate in women with RPL and underlying immune conditions. However, these 
      results should be interpreted with caution as studies are limited by low number 
      of participants and the non-randomized design, which represent seriously biases. 
      Future randomized controlled trials in women with RPL and underlying immune 
      conditions are needed before using IVIG in a clinical setting.
CI  - (c) 2022. The Author(s).
FAU - Habets, Denise H J
AU  - Habets DHJ
AUID- ORCID: 0000-0001-7018-3226
AD  - Department of Obstetrics and Gynecology, Maastricht University Medical Centre 
      (MUMC+), Maastricht, The Netherlands. denise.habets@maastrichtuniversity.nl.
AD  - Department of Transplantation Immunology, Maastricht University Medical Centre 
      (MUMC+), Maastricht, The Netherlands. denise.habets@maastrichtuniversity.nl.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands. denise.habets@maastrichtuniversity.nl.
FAU - Pelzner, Kim
AU  - Pelzner K
AD  - Department of Obstetrics and Gynecology, Maastricht University Medical Centre 
      (MUMC+), Maastricht, The Netherlands.
FAU - Wieten, Lotte
AU  - Wieten L
AD  - Department of Transplantation Immunology, Maastricht University Medical Centre 
      (MUMC+), Maastricht, The Netherlands.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands.
FAU - Spaanderman, Marc E A
AU  - Spaanderman MEA
AD  - Department of Obstetrics and Gynecology, Maastricht University Medical Centre 
      (MUMC+), Maastricht, The Netherlands.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands.
FAU - Villamor, Eduardo
AU  - Villamor E
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands.
AD  - Department of Pediatrics, Maastricht University Medical Centre (MUMC+), 
      Maastricht, The Netherlands.
FAU - Al-Nasiry, Salwan
AU  - Al-Nasiry S
AD  - Department of Obstetrics and Gynecology, Maastricht University Medical Centre 
      (MUMC+), Maastricht, The Netherlands.
AD  - GROW School for Oncology and Developmental Biology, Maastricht University, 
      Maastricht, The Netherlands.
LA  - eng
GR  - Academic Incentive Maastricht/maastricht universitair medisch centrum/
PT  - Journal Article
PT  - Review
DEP - 20220311
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian 
      Society of Allergy and Clinical Immunology
JID - 101244313
PMC - PMC8917719
OTO - NOTNLM
OT  - IVIG
OT  - RPL
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2022/03/13 06:00
MHDA- 2022/03/13 06:01
PMCR- 2022/03/11
CRDT- 2022/03/12 05:21
PHST- 2021/07/27 00:00 [received]
PHST- 2022/02/20 00:00 [accepted]
PHST- 2022/03/12 05:21 [entrez]
PHST- 2022/03/13 06:00 [pubmed]
PHST- 2022/03/13 06:01 [medline]
PHST- 2022/03/11 00:00 [pmc-release]
AID - 10.1186/s13223-022-00660-8 [pii]
AID - 660 [pii]
AID - 10.1186/s13223-022-00660-8 [doi]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2022 Mar 11;18(1):23. doi: 
      10.1186/s13223-022-00660-8.